CorporateRanbaxy gets nod to sell Ran-Simvastatin tablets in Canada
Ranbaxy Laboratories, received the final approval in Canada to manufacture and market Ran-Simvastatin tablets from Health Canada, Therapeutic Products Directorate. The total generic market size of Simvastatin tablets in Canada is $CAD153 million.
- Zandu Pharma Q1 profit doubles at Rs 11.12 cr - Ranbaxy gets Canada"s nod to mkt anti-hypertension drug - Teva Pharma recalls anti-anxiety drug Propofol - Shasun to invest Rs 100 cr for setting up new Vizag plant - Ranbaxy recalls skin disease drugs from US - Pharma, healthcare industry disappointed with Budget
Ranbaxy has got the approval for Ran-Simvastatin in 5, 10, 20 and 40 mg strengths, through its wholly-owned subsidiary Ranbaxy Pharmaceuticals- Canada Inc (RPCI), Gurgaon-based (RPCI) said in a statement.
“We look forward to marketing this organically developed product in all strengths that will be commercialised at an affordable price. Ran-Simvastatin represents the second approval granted to RPCI in July,” said Paul Drake, President RPCI.
On Monday, the Pharmaceutical firm had received approval from the Canadian drug regulator TPD to market and manufacture "Ran-Amlodipine tablets", used in treating hypertensions.